Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yunxia Li

Showing results (451-460 of 458) with videos related to

Pageof 46
Sort By:
You have reached the last page of results.This site can display upto 458 results.
ACS Medicinal Chemistry Letters|November 21, 2017
Correction to "Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors"Jeffrey W Johannes, Stephanie Bates, Carl Beigie, et al.
ACS Medicinal Chemistry Letters|February 16, 2017
Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 InhibitorsJeffrey W Johannes, Stephanie Bates, Carl Beigie, et al.
The Lancet. Oncology|October 5, 2023
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trialXiangyu Gao, Nong Xu, Ziyu Li, et al.
CA: a Cancer Journal for Clinicians|November 25, 2025
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trialLingying Wu, Jing Wang, Qingshui Li, et al.
Lancet (London, England)|October 19, 2024
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in ChinaXiaohua Wu, Yang Sun, Hongying Yang, et al.
Nature Communications|March 14, 2026
Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trialYang Sun, Hongying Yang, Jing Wang, et al.
Journal of Orthopaedic Translation|September 11, 2024
Diagnosis and treatment of anterior cruciate ligament injuries: Consensus of Chinese experts part II: Graft selection and clinical outcome evaluationTianwu Chen, Xizhuang Bai, Lunhao Bai, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Population-specific brain charts reveal Chinese-Western differences in neurodevelopmental trajectoriesLianglong Sun, Wen Qin, Xinyuan Liang, et al.
Pageof 46

Showing results (451-460 of 458) with videos related to

Sort By:
Pageof 46
You have reached the last page of results.This site can display upto 458 results.
ACS Medicinal Chemistry Letters|November 21, 2017
Correction to "Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors"Jeffrey W Johannes, Stephanie Bates, Carl Beigie, et al.
ACS Medicinal Chemistry Letters|February 16, 2017
Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 InhibitorsJeffrey W Johannes, Stephanie Bates, Carl Beigie, et al.
The Lancet. Oncology|October 5, 2023
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trialXiangyu Gao, Nong Xu, Ziyu Li, et al.
CA: a Cancer Journal for Clinicians|November 25, 2025
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trialLingying Wu, Jing Wang, Qingshui Li, et al.
Lancet (London, England)|October 19, 2024
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in ChinaXiaohua Wu, Yang Sun, Hongying Yang, et al.
Nature Communications|March 14, 2026
Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trialYang Sun, Hongying Yang, Jing Wang, et al.
Journal of Orthopaedic Translation|September 11, 2024
Diagnosis and treatment of anterior cruciate ligament injuries: Consensus of Chinese experts part II: Graft selection and clinical outcome evaluationTianwu Chen, Xizhuang Bai, Lunhao Bai, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Population-specific brain charts reveal Chinese-Western differences in neurodevelopmental trajectoriesLianglong Sun, Wen Qin, Xinyuan Liang, et al.
Pageof 46